Literature DB >> 2145582

Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis.

M P Protti1, A A Manfredi, C Straub, J F Howard, B M Conti-Tronconi.   

Abstract

In myasthenia gravis an autoimmune response against the nicotinic acetylcholine receptor (AChR) occurs. The alpha subunit of the AChR contains both the epitope(s) that dominates the antibody response (main immunogenic region) and epitopes involved in T helper cell sensitization. In this study, overlapping synthetic peptides corresponding to the complete AChR alpha-subunit sequence were used to propagate polyclonal AChR-specific T helper cell lines from four myasthenic patients of different HLA types. Response of the T helper lines to the individual peptides was studied. Four immunodominant sequence segments were identified--i.e., residues 48-67, 101-120, 304-322, and 419-437. These regions did not include residues known to form the main immunogenic region or the cholinergic binding site, and they frequently contained sequence motifs that have been proposed to be related to T-epitope formation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2145582      PMCID: PMC54834          DOI: 10.1073/pnas.87.19.7792

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  A rapid method for the separation of functional lymphoid cell populations of human and animal origin on PVP-silica (Percoll) density gradients.

Authors:  J T Kurnick; L Ostberg; M Stegagno; A K Kimura; A Orn; O Sjöberg
Journal:  Scand J Immunol       Date:  1979       Impact factor: 3.487

2.  Interaction of [125I]-alpha-bungarotoxin with acetylcholine receptor from Torpedo californica.

Authors:  S G Blanchard; U Quast; K Reed; T Lee; M I Schimerlik; R Vandlen; T Claudio; C D Strader; H P Moore; M A Raftery
Journal:  Biochemistry       Date:  1979-05-15       Impact factor: 3.162

3.  Elapid neurotoxins. Purification, characterization, and immunochemical studies of -bungarotoxin.

Authors:  D G Clark; D D Macmurchie; E Elliott; R G Wolcott; A M Landel; M A Raftery
Journal:  Biochemistry       Date:  1972-04-25       Impact factor: 3.162

4.  Production and assay of antibodies to acetylcholine receptors.

Authors:  J Lindstrom; B Einarson; S Tzartos
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

5.  Purification of Torpedo californica post-synaptic membranes and fractionation of their constituent proteins.

Authors:  J Elliott; S G Blanchard; W Wu; J Miller; C D Strader; P Hartig; H P Moore; J Racs; M A Raftery
Journal:  Biochem J       Date:  1980-03-01       Impact factor: 3.857

6.  Specific binding of perhydrohistrionicotoxin to Torpedo acetylcholine receptor.

Authors:  J Elliott; S M Dunn; S G Blanchard; M A Raftery
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

7.  Reactivity of inducer cell subsets and T8-cell activation during the human autologous mixed lymphocyte reaction.

Authors:  P L Romain; C Morimoto; J F Daley; L S Palley; E L Reinherz; S F Schlossman
Journal:  Clin Immunol Immunopathol       Date:  1984-01

8.  Cloning and sequence analysis of calf cDNA and human genomic DNA encoding alpha-subunit precursor of muscle acetylcholine receptor.

Authors:  M Noda; Y Furutani; H Takahashi; M Toyosato; T Tanabe; S Shimizu; S Kikyotani; T Kayano; T Hirose; S Inayama
Journal:  Nature       Date:  1983 Oct 27-Nov 2       Impact factor: 49.962

9.  Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies.

Authors:  S J Tzartos; M E Seybold; J M Lindstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

10.  Use of synthetic peptides to establish anti-human acetylcholine receptor CD4+ cell lines from myasthenia gravis patients.

Authors:  M P Protti; A A Manfredi; C Straub; X D Wu; J F Howard; B M Conti-Tronconi
Journal:  J Immunol       Date:  1990-03-01       Impact factor: 5.422

View more
  20 in total

1.  Intercommunication between the neuroendocrine and immune systems: focus on myasthenia gravis.

Authors:  Jacqueline Mays; Cherié L Butts
Journal:  Neuroimmunomodulation       Date:  2011-09-22       Impact factor: 2.492

Review 2.  Current and future therapies for myasthenia gravis.

Authors:  Q Yi; A K Lefvert
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

Review 3.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 4.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 5.  The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies.

Authors:  S J Tzartos; M T Cung; P Demange; H Loutrari; A Mamalaki; M Marraud; I Papadouli; C Sakarellos; V Tsikaris
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

6.  Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs.

Authors:  Y Katz-Levy; S L Kirshner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

Review 7.  Functional defect in regulatory T cells in myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Julie Rowin; Qin Li Jiang; Jian Rong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

8.  T helper cell recognition of muscle acetylcholine receptor in myasthenia gravis. Epitopes on the gamma and delta subunits.

Authors:  A A Manfredi; M P Protti; M W Dalton; J F Howard; B M Conti-Tronconi
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

9.  Myasthenia gravis. CD4+ T epitopes on the embryonic gamma subunit of human muscle acetylcholine receptor.

Authors:  M P Protti; A A Manfredi; X D Wu; L Moiola; M W Dalton; J F Howard; B M Conti-Tronconi
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

10.  Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma.

Authors:  T Morisaki; D L Morton; A Uchiyama; D Yuzuki; A Barth; D S Hoon
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.